Generic placeholder image

Current Hypertension Reviews

Editor-in-Chief

ISSN (Print): 1573-4021
ISSN (Online): 1875-6506

Review Article

Recent Insights on Drug Delivery System in Hypertension: From Bench to Market

Author(s): Gaurav Sharma and Abhishek Sharma*

Volume 19, Issue 2, 2023

Published on: 01 August, 2023

Page: [93 - 105] Pages: 13

DOI: 10.2174/1573402119666230707120846

Price: $65

Abstract

Hypertension is a significant hazardous aspect for several diseases, like cardiovascular disease, kidney failure, and brain disease. Hypertension has become the most lethal condition globally, affecting approximately 1 billion people aged around 30-79 years worldwide. In the year 2022, India was ranked 170th for men and 193rd for women for HTN diagnosis rates among 200 countries worldwide. The main risk factor for cardiac failure and stroke is hypertension. The conventional classes of antihypertensive medications currently available have some side effects. Previously, hypertension has been discussed by various researchers using conventional drug-targeting methods such as ACE inhibitors, aldosterone inhibitors, or renin inhibitors. Recently, novel drug delivery technologies utilizing nanoparticles and new pharmacological classes like ACE2 and APA inhibitors have been studied for the medication of hypertension. In this review, we have covered the epidemiology of hypertension in India, its pathophysiology, medications used in the management of hypertension using nanotechnology, and antihypertensive drugs currently available in the market that are approved and patented. Finally, we have covered how hypertension can be managed with the help of smart devices and artificial intelligence (AI) for improved therapy.

Keywords: Hypertension, pathophysiology, anti-hypertensive, treatment, nanotechnology, artificial intelligence.

Graphical Abstract
[1]
Roth GA, Abate D, Abate KH. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159): 1736-88.
[http://dx.doi.org/10.1016/S0140-6736(18)32203-7] [PMID: 30496103]
[2]
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365(9455): 217-23.
[http://dx.doi.org/10.1016/S0140-6736(05)17741-1] [PMID: 15652604]
[3]
Forouzanfar MH, Liu P, Roth GA. et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA 2017; 317(2): 165-82.
[http://dx.doi.org/10.1001/jama.2016.19043] [PMID: 28097354]
[4]
Geldsetzer P, Manne-Goehler J, Marcus ME. et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. Lancet 2019; 394(10199): 652-62.
[http://dx.doi.org/10.1016/S0140-6736(19)30955-9] [PMID: 31327566]
[5]
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol 2020; 16(4): 223-37.
[http://dx.doi.org/10.1038/s41581-019-0244-2] [PMID: 32024986]
[6]
Zhou B, Bentham J, Di Cesare M. et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017; 389(10064): 37-55.
[http://dx.doi.org/10.1016/S0140-6736(16)31919-5] [PMID: 27863813]
[7]
Chobanian AV, Bakris GL, Black HR. et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-52.
[http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2] [PMID: 14656957]
[8]
Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension 2017; 70(4): 660-7.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.117.07802] [PMID: 28784646]
[9]
O’Brien E, Parati G, Stergiou G. et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31(9): 1731-68.
[http://dx.doi.org/10.1097/HJH.0b013e328363e964] [PMID: 24029863]
[10]
Williamson JD, Supiano MA, Applegate WB. et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. JAMA 2016; 315(24): 2673-82.
[http://dx.doi.org/10.1001/jama.2016.7050] [PMID: 27195814]
[11]
Zhou B, Bentham J, Di Cesare M. et al. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: A pooled analysis of 1018 population-based measurement studies with 88.6 million participants. Int J Epidemiol 2018; 47(3): 872-883i.
[http://dx.doi.org/10.1093/ije/dyy016] [PMID: 29579276]
[12]
Zhou B, Wang H, Yang J. et al. How can China benefit from the achievement of the 25×25 hypertension control goal in 2025? BMC Med 2017; 15(1): 32.
[http://dx.doi.org/10.1186/s12916-017-0798-z] [PMID: 28193219]
[13]
Anchala R, Kannuri NK, Pant H. et al. Prevalence of hypertension and its association with obesity: A cross-sectional survey in urban and rural Rajasthan. J Hum Hypertens 2015; 29(9): 592-9.
[http://dx.doi.org/10.1038/jhh.2014.125]
[14]
Dandona L, Dandona R, Kumar GA. et al. India State-Level Disease Burden Initiative Collaborators. Nations within a nation: variations in epidemiological transition across the states of India, 1990–2016 in the Global Burden of Disease Study. Lancet 2017; 390(10111): 2437-60.
[http://dx.doi.org/10.1016/S0140-6736(17)32804-0] [PMID: 29150201]
[15]
Anchala R, Kannuri NK, Pant H. et al. Hypertension in India. J Hypertens 2014; 32(6): 1170-7.
[http://dx.doi.org/10.1097/HJH.0000000000000146] [PMID: 24621804]
[16]
Mohanan PP. Cardiology blooms at ACC 2014 at Washington DC but no cherry blossoms. Indian Heart J 2014; 66(2): 253-4.
[http://dx.doi.org/10.1016/j.ihj.2014.04.002]
[17]
Thankappan KR, Shah B, Mathur P, Sarma PS, Srinivas G, Mini GK. Prevalence, awareness, treatment, and control of hypertension in a rural population in South India. J Hum Hypertens 2006; 20(5): 383-7.
[http://dx.doi.org/10.1038/sj.jhh.1001984]
[18]
ICMR-INDIAB Collaborative Study Group. Prevalence of hypertension in Indian adults: Results from the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study. J Hum Hypertens 2015; 29(4): 204-9.
[http://dx.doi.org/10.1038/jhh.2014.57]
[19]
Mohan B, Kumar N, Aslam N. et al. Prevalence of sustained hypertension and obesity in urban and rural school going children in Ludhiana. Indian Heart J 2004; 56(4): 310-4.
[http://dx.doi.org/10.1016/S0019-4832(04)70088-5] [PMID: 15586739]
[20]
Choudhary M, Gupta SP, Yadav R. et al. Medication adherence and its association with blood pressure control among hypertensive patients attending a tertiary care hospital. J Clin Diagn Res 2017; 11(7): OC05-8.
[http://dx.doi.org/10.7860/JCDR/2017/27585.10133]
[21]
Kario K. Essential hypertension: Pathophysiology and clinical management. Lancet 2015; 386(9995): 1545-61.
[http://dx.doi.org/10.1016/S0140-6736(15)60734-3]
[22]
Khera R, Lu Y, Lu J. et al. Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: Nationally representative cross sectional study. BMJ 2018; 362: k2357.
[http://dx.doi.org/10.1136/bmj.k2357] [PMID: 29997129]
[23]
Rubio-Guerra AF. New guides of American College of Cardiology/American Heart Association hypertension for the treatment of high blood pressure. A jump in the right direction? Medicina Interna de México 2018; 34(2)
[http://dx.doi.org/10.24245/mim.v34i2.2015]
[24]
Joyner MJ, Charkoudian N, Wallin BG. Sympathetic nervous system and blood pressure in humans: Individualized patterns of regulation and their implications. Hypertension 2010; 56(1): 10-6.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.140186] [PMID: 20497993]
[25]
Delacroix S, Chokka RG. Hypertension: Pathophysiology and treatment. J Neurol Neurophysiol 2014; 5(6)
[http://dx.doi.org/10.4172/2155-9562.1000250]
[26]
Leoncini G, Viazzi F, De Cosmo S, Russo G, Fioretto P, Pontremoli R. Blood pressure reduction and RAAS inhibition in diabetic kidney disease: Therapeutic potentials and limitations. J Nephrol 2020; 33(5): 949-63.
[http://dx.doi.org/10.1007/s40620-020-00803-3] [PMID: 32681470]
[27]
Miguel-Jiménez S, Carvajal-Serna M, Calvo S. et al. Does melatonin exert its effect on ram sperm capacitation through nitric oxide synthase regulation? Int J Mol Sci 2020; 21(6): 2093.
[http://dx.doi.org/10.3390/ijms21062093] [PMID: 32197481]
[28]
Ghatage T, Goyal SG, Dhar A, Bhat A. Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies. Hypertens Res 2021; 44(7): 740-55.
[http://dx.doi.org/10.1038/s41440-021-00643-z] [PMID: 33731923]
[29]
Chen X, Du J, Wu X, Cao W, Sun S. Global burden attributable to high sodium intake from 1990 to 2019. Nutr Metab Cardiovasc Dis 2021; 31(12): 3314-21.
[http://dx.doi.org/10.1016/j.numecd.2021.08.033] [PMID: 34627699]
[30]
Tanaka M, Itoh H. Hypertension as a metabolic disorder and the novel role of the gut. Curr Hypertens Rep 2019; 21(8): 63.
[http://dx.doi.org/10.1007/s11906-019-0964-5] [PMID: 31236708]
[31]
Marques da Silva P, Lima MJ, Neves PM, Espiga de Macedo M. Prevalence of cardiovascular risk factors and other comorbidities in patients with hypertension in Portuguese primary health care populations: The PRECISE study. Revista Portuguesa de Cardiologia 2019; 38(6): 427-37.
[http://dx.doi.org/10.1016/j.repce.2018.09.012] [PMID: 31307727]
[32]
Litwin M. Kułaga Z. Obesity, metabolic syndrome, and primary hypertension. Pediatr Nephrol 2021; 36(4): 825-37.
[http://dx.doi.org/10.1007/s00467-020-04579-3] [PMID: 32388582]
[33]
Chung AA, Millner PR. Accessory renal artery stenosis and secondary hypertension. Case Rep Nephrol 2020; 2020: 1-4.
[http://dx.doi.org/10.1155/2020/8879165] [PMID: 32774955]
[34]
Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71(6): 1269-324.
[http://dx.doi.org/10.1161/HYP.0000000000000066] [PMID: 29133354]
[35]
Gupta R, Malhotra A, Malhotra P. Study of prescribing pattern of drugs used in the treatment of hypertension in a tertiary care teaching hospital in North India: an observational study. J Res Med Sci 2018; 6(7): 2380.
[http://dx.doi.org/10.18203/2320-6012.ijrms20182821]
[36]
Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Libr 2018; 2018(4): CD001841.
[http://dx.doi.org/10.1002/14651858.CD001841.pub3] [PMID: 29667175]
[37]
Bhusal M, Aryal E, Bhattarai S, Shrestha SB, Rajouria A. Iatrogenic Cushing syndrome due to application of potent topical corticosteroid: A case report. Nepal Journal of Dermatology. Venereology & Leprology 2019; 17(1): 73-5.
[http://dx.doi.org/10.3126/njdvl.v17i1.23291]
[38]
Roush GC, Sica DA. Diuretics for hypertension: A review and update. Am J Hypertens 2016; 29(10): 1130-7.
[http://dx.doi.org/10.1093/ajh/hpw030] [PMID: 27048970]
[39]
Sinha AD, Agarwal R. Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD. Clin J Am Soc Nephrol 2019; 14(5): 757-64.
[http://dx.doi.org/10.2215/CJN.04330418] [PMID: 30425103]
[40]
Kochetkov AI. Thiazide and thiazide-like diuretics in the treatment of arterial hypertension: Are there any differences? Ration Pharmacother Cardiol 2020; 16(6): 994-1001.
[http://dx.doi.org/10.20996/1819-6446-2020-16-09]
[41]
Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother 2014; 15(5): 605-21.
[http://dx.doi.org/10.1517/14656566.2014.879117] [PMID: 24456327]
[42]
Thakur R, Sharma A. An overview of mucoadhesive thermoreversible nasal gel. Asian J Pharm Res Dev 2021; 9(4): 158-68.
[43]
Martins VM, Ziegelmann PK, Helal L. et al. Thiazide diuretics alone or in combination with a potassium-sparing diuretic on blood pressure-lowering in patients with primary hypertension: Protocol for a systematic review and network meta-analysis. Syst Rev 2022; 11(1): 23.
[http://dx.doi.org/10.1186/s13643-022-01890-y] [PMID: 35135630]
[44]
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Libr 2017; 2017(1): CD002003.
[http://dx.doi.org/10.1002/14651858.CD002003.pub5] [PMID: 28107561]
[45]
Sari OM. Studi penggunaan obat golongan beta-blocker pada pasien Rawat inap rumah sakit Ansari Saleh Banjarmasin. J Farmasi Udayana 2020.
[http://dx.doi.org/10.24843/JFU.2020.v09.i02.p07]
[46]
Kaplowitz GJ. Dental management of the medically compromised patient. 1997.
[http://dx.doi.org/10.14219/jada.archive.1997.0331]
[47]
Frishman WH. Beta-adrenergic blockers. mechanism of action, pharmacokinetics, clinical indications, side effects, and contradictions. Cardiol Clin 1998; 16(3): 429-44.
[http://dx.doi.org/10.1016/s0733-8651(05)70052-6]
[48]
Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Libr 2020; 2020(10): CD012569.
[http://dx.doi.org/10.1002/14651858.CD012569.pub2] [PMID: 33089502]
[49]
Daskaya-Dikmen C, Yucetepe A, Karbancioglu-Guler F, Daskaya H, Ozcelik B. Angiotensin-I-converting enzyme (ACE)-inhibitory peptides from plants. Nutrients 2017; 9(4): 316.
[http://dx.doi.org/10.3390/nu9040316] [PMID: 28333109]
[50]
Agarwal S, Thakur A, Sharma A. Development and evaluation of ketoprofen loaded floating microspheres for sustained delivery. Mater Today Proc 2022; 68: 647-52.
[http://dx.doi.org/10.1016/j.matpr.2022.05.299]
[51]
Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med 2019; 86(9): 601-7.
[http://dx.doi.org/10.3949/ccjm.86a.18024] [PMID: 31498767]
[52]
Meng J, Xiao G, Zhang J. et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020; 9(1): 757-60.
[http://dx.doi.org/10.1080/22221751.2020.1746200] [PMID: 32228222]
[53]
Godfraind T. Discovery and development of calcium channel blockers. Front Pharmacol 2017; 8: 286.
[http://dx.doi.org/10.3389/fphar.2017.00286]
[54]
Chen N, Zhou M, Yang M. et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Libr 2010; (8): CD003654.
[http://dx.doi.org/10.1002/14651858.CD003654.pub4] [PMID: 20687074]
[55]
Sharma A, Harikumar SL. Quality by design approach for development and optimization of nitrendipine-loaded niosomal gel for accentuated transdermal delivery. Int J Appl Pharm 2020; 12(5): 181-9.
[http://dx.doi.org/10.22159/ijap.2020v12i5.38639]
[56]
Sharma A, Singh AP, Harikumar SL. Development and optimization of nanoemulsion based gel for enhanced transdermal delivery of nitrendipine using box-behnken statistical design. Drug Dev Ind Pharm 2020; 46(2): 329-42.
[http://dx.doi.org/10.1080/03639045.2020.1721527] [PMID: 31976777]
[57]
Sharma A, Sharma R, Singh Bora K, Harikumar SL. Pharmacokinetic investigation of nitrendipine encapsulated niosomal gel in rat plasma by RP-HPLC method. Mater Today Proc 2022; 68: 653-7.
[http://dx.doi.org/10.1016/j.matpr.2022.05.301]
[58]
Lepor H. Alpha-blockers in the treatment of benign prostatic hyperplasia: mechanism of action, efficacy, and safety. Rev Urol 2007; 9 (Suppl. 3): S18-25.
[http://dx.doi.org/10.3909/riu0155]
[59]
Saruta T. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Jpn J Clin Med 2005; 63(6): 952-8.
[http://dx.doi.org/10.1038/hr.2014.68] [PMID: 15948375]
[60]
Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens 2017; 11(1): 54-65.
[http://dx.doi.org/10.1016/j.jash.2016.11.007] [PMID: 28057444]
[61]
Mulder E, Ghossein-Doha C, Appelman E. et al. Study protocol for the randomized controlled EVA (early vascular adjustments) trial: tailored treatment of mild hypertension in pregnancy to prevent severe hypertension and preeclampsia. BMC Pregnancy Childbirth 2020; 20(1): 775.
[http://dx.doi.org/10.1186/s12884-020-03475-w] [PMID: 33308198]
[62]
Tarkin JM, Kaski JC. Vasodilator therapy: Nitrates and nicorandil. Cardiovasc Drugs Ther 2016; 30(4): 367-78.
[http://dx.doi.org/10.1007/s10557-016-6668-z] [PMID: 27311574]
[63]
Kincaid-Smith P. Vasodilator drugs in the treatment of hypertension. Med J Aust 1985; 142(8): 450-3.
[http://dx.doi.org/10.5694/j.1326-5377.1985.tb113448.x] [PMID: 3884988]
[64]
Nappi J, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag 2011; 7(1): 353-63.
[http://dx.doi.org/10.2147/VHRM.S13779] [PMID: 21731887]
[65]
Gao Q, Xu L, Cai J. New drug targets for hypertension: A literature review. Biochim Biophys Acta Mol Basis Dis 2021; 1867(3): 166037.
[http://dx.doi.org/10.1016/j.bbadis.2020.166037] [PMID: 33309796]
[66]
Nadeem S, Batisky DL. Aliskiren, the first direct renin inhibitor: Assessing a role in pediatric hypertension and kidney diseases. Pediatr Nephrol 2014; 29(11): 2105-11.
[http://dx.doi.org/10.1007/s00467-013-2716-0] [PMID: 24337365]
[67]
Ramya K, Suresh R, Kumar HY, Kumar BRP, Murthy NBS. Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules. Bioorg Med Chem 2020; 28(10): 115466.
[http://dx.doi.org/10.1016/j.bmc.2020.115466] [PMID: 32247750]
[68]
Leontsinis I, Mantzouranis M, Tsioufis P, Andrikou I, Tsioufis C. Recent advances in managing primary hypertension. Fac Rev 2020; 9: 4.
[http://dx.doi.org/10.12703/b/9-4] [PMID: 33659936]
[69]
Szeto CC, Sugano K, Wang JG. et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: Joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut 2020; 69(4): 617-29.
[http://dx.doi.org/10.1136/gutjnl-2019-319300] [PMID: 31937550]
[70]
Kitt J, Fox R, Tucker KL, McManus RJ. New approaches in hypertension management: A review of current and developing technologies and their potential impact on hypertension care. Curr Hypertens Rep 2019; 21(6): 44.
[http://dx.doi.org/10.1007/s11906-019-0949-4] [PMID: 31025117]
[71]
Adetunji CO, Michael OS, Rathee S. et al. Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight. Materials Today Advances 2022; 13: 100198.
[http://dx.doi.org/10.1016/j.mtadv.2021.100198]
[72]
Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res 2015; 116(6): 1074-95.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.303603] [PMID: 25767291]
[73]
Jackson TC, Patani BO, Ekpa DE. Nanotechnology in diagnosis: A review. Adv Nanopart 2017; 6(3): 93-102.
[http://dx.doi.org/10.4236/anp.2017.63008]
[74]
Davis J, Oparil S. Novel medical treatments for hypertension and related comorbidities. Curr Hypertens Rep 2018; 20(10): 90.
[http://dx.doi.org/10.1007/s11906-018-0890-y] [PMID: 30145617]
[75]
Sharma A, Babu Sharma R, Verma A, Thakur R. Insight on nanoparticles, green synthesis and applications in drug delivery system-a comprehensive review. Int J Life Sci Pharma Res 2022; 12(5): 68-84.
[http://dx.doi.org/10.22376/ijpbs/lpr.2022.12.5.P68-84]
[76]
Zhang Y, Wang Q, Li H. et al. Design and evaluation of a biodegradable PLGA-based nanosuspension for the delivery of an anti-cancer agent. J Biomed Nanotechnol 2022; 18: 660.
[http://dx.doi.org/10.1166/jbn.2022.3413]
[77]
Li Y, Wang L, Li Y. et al. Preparation and characterization of chitosan-coated magnetic nanoparticles for drug delivery applications. Particuology 2022; 64: 153.
[http://dx.doi.org/10.1016/j.partic.2022.02.001]
[78]
Ekambaram P, Abdul Hasan Sathali A. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm 2011; 3(3): 216-20.
[http://dx.doi.org/10.4103/0975-1483.83765] [PMID: 21897661]
[79]
Chonkar AD, Rao JV, Managuli RS. et al. Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation. Eur J Pharm Biopharm 2016; 103: 179-91.
[http://dx.doi.org/10.1016/j.ejpb.2016.04.001] [PMID: 27063592]
[80]
Kara A, Vassiliadou A, Ongoren B. et al. Engineering 3d printed microfluidic chips for the fabrication of nanomedicines. Pharmaceutics 2021; 13(12): 2134.
[http://dx.doi.org/10.3390/pharmaceutics13122134] [PMID: 34959415]
[81]
Choudhary R, Bodla RB, Gupta G. et al. Nanoparticle-based drug delivery systems: promising approaches against infections. Braz J Infect Dis 2018; 22(2): 86-99.
[http://dx.doi.org/10.1016/j.bjid.2018.02.001]
[82]
Prajapati JB, Katariya H, Patel R. Peyer’e patch targeting of isradipine loaded Solid Lipid Nanoparticles: it’s cellular uptake study. Journal of Drug Delivery ADVERSE EVENTS: A SYSTEMATIC META-ANALYSIS. J Am Coll Cardiol 2018; 69(11)
[http://dx.doi.org/10.1016/S0735-1097(17)34307-3]
[83]
Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: Characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv 2016; 23(2): 395-404.
[http://dx.doi.org/10.3109/10717544.2014.914986] [PMID: 24865287]
[84]
Sharma A, Thakur R, Sharma R. Development and optimization of candesartan cilexetil nasal gel for accentuated intranasal delivery using central composite design. Mater Today Proc 2022. In Press
[http://dx.doi.org/10.1016/j.matpr.2022.11.221]
[85]
Shirisha S, Saraswathi A, Sahoo SK, Rao YM. Formulation and evaluation of nisoldipine loaded solid lipid nanoparticles and nanostructured lipid carriers: application to transdermal delivery. Indian J Pharm Educ Res 2020; 54(2s): s117-27.
[http://dx.doi.org/10.5530/ijper.54.2s.68]
[86]
Suthar V, Butani S, Gohel M. Solid self-emulsified nanostructures of Lercanidipine hydrochloride: A potential approach to improve the fraction of the dose absorbed. J Drug Deliv Sci Technol 2016; 31: 11-21.
[http://dx.doi.org/10.1016/j.jddst.2015.11.001]
[87]
Kataria D, Zafar A, Ali J. et al. Formulation of lipid-based nanocarriers of lacidipine for improvement of oral delivery: box-Behnken design optimization, in vitro, ex vivo, and preclinical assessment. Assay Drug Dev Technol 2022; 20(1): 5-21.
[http://dx.doi.org/10.1089/adt.2021.084] [PMID: 34978917]
[88]
Chhabra G, Chuttani K, Mishra AK, Pathak K. Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev Ind Pharm 2011; 37(8): 907-16.
[http://dx.doi.org/10.3109/03639045.2010.550050] [PMID: 21401341]
[89]
Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 2007; 66(2): 227-43.
[http://dx.doi.org/10.1016/j.ejpb.2006.10.014] [PMID: 17127045]
[90]
Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Nanocarriers as treatment modalities for hypertension. Drug Deliv 2017; 24(1): 358-69.
[http://dx.doi.org/10.1080/10717544.2016.1255999] [PMID: 28165823]
[91]
Abu-Huwaij R, Hamed R, Daoud E, Alkilani A. Development and in vitro characterization of nanoemulsion-based buccal patches of valsartan. Acta Pol Pharm 2019; 76(2): 313-21.
[http://dx.doi.org/10.32383/appdr/99526]
[92]
Gorain B, Choudhury H, Kundu A. et al. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats. Colloids Surf B Biointerfaces 2014; 115: 286-94.
[http://dx.doi.org/10.1016/j.colsurfb.2013.12.016] [PMID: 24388859]
[93]
Dahash RAA, Rajab NA. Formulation and investigation of lacidipine as nanoemulsions. Iraqi J Pharm Sci 2020; 29(1): 41-54.
[http://dx.doi.org/10.31351/vol29iss1pp41-54]
[94]
Fernandes GJ, Kumar L, Sharma K, Tunge R, Rathnanand M. A review on solubility enhancement of carvedilol-a BCS Class II drug. J Pharm Innov 2018; 13(3): 197-212.
[http://dx.doi.org/10.1007/s12247-018-9319-z]
[95]
ElKasabgy NA, Elsayed I, Elshafeey AH. Design of lipotomes as a novel dual functioning nanocarrier for bioavailability enhancement of lacidipine: In-vitro and in-vivo characterization. Int J Pharm 2014; 472(1-2): 369-79.
[http://dx.doi.org/10.1016/j.ijpharm.2014.06.048] [PMID: 24979531]
[96]
Burkey BF, Hoglen NC, Inskeep P, Wyman M, Hughes TE, Vath JE. Preclinical efficacy and safety of the novel antidiabetic, antiobesity metap2 inhibitor ZGN-1061. J Pharmacol Exp Ther 2018; 365(2): 301-13.
[http://dx.doi.org/10.1124/jpet.117.246272] [PMID: 29491038]
[97]
Seth M, Hussain ME, Pasha S, Fahim M. Effects of a novel ACE inhibitor, 3-(3-thienyl)-L-alanyl-ornithyl-proline, on endothelial vasodilation and hepatotoxicity in L-NAME-induced hypertensive rats. Drug Des Devel Ther 2016; 10: 1533-42.
[http://dx.doi.org/10.2147/DDDT.S77761] [PMID: 27143859]
[98]
Wilson AJ, Chang B, Chin BC, Taglinenti AJ, Folsom N, Percec I. Abstract 63: A quantitative analysis of different botulinum toxin formulations: A randomized double blind prospective clinical trial of comparative dynamic strain reduction. Plast Reconstr Surg 2015; 135: 50-1.
[http://dx.doi.org/10.1097/01.prs.0000465511.62305.6c]
[99]
Kim HK, Hwang SH, Abdi S. Tempol ameliorates and prevents mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain. Front Pharmacol 2017; 7(JAN): 532.
[http://dx.doi.org/10.3389/fphar.2016.00532] [PMID: 28138318]
[100]
Dzhoyashvili N, Iyer S, Chen Y. et al. The novel GC-A/CGMP activating designer M-ATRIAL natriuretic peptide potently reduces blood pressure in a genetic model of hypertension and potentiates the actions of furosemide. J Am Coll Cardiol 2019; 73(9): 1713.
[http://dx.doi.org/10.1016/S0735-1097(19)32319-8]
[101]
Pozdnyakov Y, Kostyukova A, Khokhlov A. et al. Novel soluble guanylyl cyclase activator for the treatment of hypertension and metabolic syndrome. Eur Heart J 2020; 41 (Suppl_2): ehaa946.1224.
[http://dx.doi.org/10.1093/ehjci/ehaa946.1224]
[102]
Nesbitt SD. Firibastat: A novel treatment for hypertension. Curr Hypertens Rep 2021; 23(12): 46.
[http://dx.doi.org/10.1007/s11906-021-01163-4] [PMID: 34950965]
[103]
Barone M. Recombinant human angiotensin-converting enzyme 2 and COVID-19 acute respiratory distress syndrome: A theoretical or a real resource?. Eurasian J Med Oncol 2020.
[http://dx.doi.org/10.14744/ejmo.2020.47992]
[104]
Hanrahan JP, Seferovic JP, Wakefield JD. et al. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia 2020; 63(4): 733-43.
[http://dx.doi.org/10.1007/s00125-019-05062-x] [PMID: 31858186]
[105]
Ahmed HA, Ishrat T, Pillai B. et al. RAS modulation prevents progressive cognitive impairment after experimental stroke: A randomized, blinded preclinical trial. J Neuroinflammation 2018; 15(1): 229.
[http://dx.doi.org/10.1186/s12974-018-1262-x] [PMID: 30103772]
[106]
Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor Tenapanor: two trials in healthy volunteers. Clin Drug Investig 2018; 38(4): 341-51.
[http://dx.doi.org/10.1007/s40261-017-0614-0] [PMID: 29363027]
[107]
Markham A. Tenapanor: First Approval. Drugs 2019; 79(17): 1897-903.
[http://dx.doi.org/10.1007/s40265-019-01215-9] [PMID: 31677150]
[108]
Mathews JL, Schweighardt A. The role of natriuretic peptides in the pathophysiology and treatment of heart failure. In: Emerging applications, perspectives, and discoveries in cardiovascular research. 2017.
[http://dx.doi.org/10.4018/978-1-5225-2092-4.ch001]
[109]
Massie BM, O’Connor CM, Metra M. et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363(15): 1419-28.
[http://dx.doi.org/10.1056/NEJMoa0912613] [PMID: 20925544]
[110]
Enevoldsen FC, Sahana J, Wehland M, Grimm D, Infanger M, Krüger M. Endothelin receptor antagonists: Status quo and future perspectives for targeted therapy. J Clin Med 2020; 9(3): 824.
[http://dx.doi.org/10.3390/jcm9030824] [PMID: 32197449]
[111]
Treiber A, Delahaye S, Seeland S, Gnerre C. The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern. Pharmacol Res Perspect 2020; 8(4): e00619.
[http://dx.doi.org/10.1002/prp2.619] [PMID: 32613761]
[112]
Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: Entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2014; 70(12): 1479-86.
[http://dx.doi.org/10.1007/s00228-014-1755-8] [PMID: 21541781]
[113]
Bartolucci R, Dosne AG, Csonka D, Pérez-Ruixo JJ, Magni P, Poggesi I. A population pharmacokinetic model of macitentan and its active metabolite Aprocitentan in healthy volunteers and patients with pulmonary arterial hypertension. Clin Pharmacokinet 2021; 60(12): 1605-19.
[http://dx.doi.org/10.1007/s40262-021-01049-3] [PMID: 34159557]
[114]
Wei CY, Tzeng IS, Lin MC, Yeh YH, Hsu CY, Kung WM. Risks of sulpiride-induced Parkinsonism in peptic ulcer and gastroesophageal reflux disease patients in Taiwan: A nationwide population-based study. Front Pharmacol 2020; 11: 433.
[http://dx.doi.org/10.3389/fphar.2020.00433] [PMID: 32390831]
[115]
Bairwa M, Pilania M, Gupta V, Yadav K. Hypertension Vaccine may be a boon to millions in developing world. Hum Vaccin Immunother 2014; 10(3): 708-13.
[http://dx.doi.org/10.4161/hv.27520] [PMID: 24365998]
[116]
Maurer P, Bachmann MF. Immunization against angiotensins for the treatment of hypertension. Clin Immunol 2010; 134(1): 89-95.
[http://dx.doi.org/10.1016/j.clim.2009.06.003] [PMID: 19577521]
[117]
Oliva RV, Bakris GL. Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014; 8(5): 330-9.
[http://dx.doi.org/10.1016/j.jash.2014.02.003] [PMID: 24631482]
[118]
Mikhail N. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus. South Med J 2015; 108(2): 91-6.
[http://dx.doi.org/10.14423/SMJ.0000000000000235] [PMID: 25688893]
[119]
Sharif NA. Novel potential treatment modalities for ocular hypertension: Focus on angiotensin and bradykinin system axes. J Ocul Pharmacol Ther 2015; 31(3): 131-45.
[http://dx.doi.org/10.1089/jop.2014.0114] [PMID: 25599263]
[120]
Chen Y, Zheng Y, Iyer SR. et al. C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts. J Mol Cell Cardiol 2019; 130: 140-50.
[http://dx.doi.org/10.1016/j.yjmcc.2019.03.024] [PMID: 30954448]
[121]
Yamakawa S, Homma T, Yamada M, Igawa Y, Yoshimura M. Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro<sup>®</sup> tablets 1.25 mg, 2.5 mg, 5 mg). Nippon Yakurigaku Zasshi 2020; 155(5): 340-50.
[http://dx.doi.org/10.1254/fpj.20016] [PMID: 32879177]
[122]
Pezik E, Gulsun T, Sahin S. Vural İ Development and characterization of pullulan-based orally disintegrating films containing amlodipine besylate. Eur J Pharm Sci 2021; 156: 105597.
[http://dx.doi.org/10.1016/j.ejps.2020.105597] [PMID: 33065224]
[123]
Fares H, DiNicolantonio JJ, O’Keefe JH, Lavie CJ. Amlodipine in hypertension: A first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart 2016; 3(2): e000473.
[http://dx.doi.org/10.1136/openhrt-2016-000473] [PMID: 27752334]
[124]
Ma W, Sun N, Duan C. et al. Effectiveness of Levoamlodipine maleate for hypertension compared with amlodipine besylate: a pragmatic comparative effectiveness study. Cardiovasc Drugs Ther 2021; 35(1): 41-50.
[http://dx.doi.org/10.1007/s10557-020-07054-1] [PMID: 32915349]
[125]
Snelder N, Ploeger BA, Luttringer O. et al. Drug effects on the CVS in conscious rats: Separating cardiac output into heart rate and stroke volume using PKPD modelling. Br J Pharmacol 2014; 171(22): n/a.
[http://dx.doi.org/10.1111/bph.12824] [PMID: 24962208]
[126]
Saputri FA, Kang D, Kusuma ASW. et al. Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. J Int Med Res 2018; 46(12): 5004-10.
[http://dx.doi.org/10.1177/0300060518788994] [PMID: 30092663]
[127]
Mukherjee D, Zha J, Menon RM, Shebley M. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. J Pharmacokinet Pharmacodyn 2018; 45(3): 443-56.
[http://dx.doi.org/10.1007/s10928-018-9574-0] [PMID: 29427135]
[128]
Mahmoud AM, Abdel-Wadood HM, Mohamed NA. Kinetic spectrophotometric method for determination of amlodipine besylate in its pharmaceutical tablets. J Pharm Anal 2012; 2(5): 334-41.
[http://dx.doi.org/10.1016/j.jpha.2012.03.002] [PMID: 29403763]
[129]
Kass RS, Arena JP. Influence of pHo on calcium channel block by amlodipine, a charged dihydropyridine compound. Implications for location of the dihydropyridine receptor. J Gen Physiol 1989; 93(6): 1109-27.
[http://dx.doi.org/10.1085/jgp.93.6.1109] [PMID: 2549176]
[130]
Khemasuwan D, Sorensen JS, Colt HG. Artificial intelligence in pulmonary medicine: Computer vision, predictive model and COVID-19. Eur Respir Rev 2020; 29(157): 200181.
[http://dx.doi.org/10.1183/16000617.0181-2020] [PMID: 33004526]
[131]
Mueller FB. AI (artificial intelligence) and hypertension research. Curr Hypertens Rep 2020; 22(9): 70.
[http://dx.doi.org/10.1007/s11906-020-01068-8] [PMID: 32852654]
[132]
Fosso Wamba S, Queiroz MM. Responsible artificial intelligence as a secret ingredient for digital health: Bibliometric analysis, insights, and research directions. Inf Syst Front 2021; •••: 1-16.
[http://dx.doi.org/10.1007/s10796-021-10142-8] [PMID: 34025210]
[133]
Amaratunga D, Cabrera J, Sargsyan D, Kostis JB, Zinonos S, Kostis WJ. Uses and opportunities for machine learning in hypertension research. Int J Cardiol Hypertens 2020; 5: 100027.
[http://dx.doi.org/10.1016/j.ijchy.2020.100027] [PMID: 33447756]
[134]
Krittanawong C, Bomback AS, Baber U, Bangalore S, Messerli FH, Wilson Tang WH. Future direction for using artificial intelligence to predict and manage hypertension. Curr Hypertens Rep 2018; 20(9): 75.
[http://dx.doi.org/10.1007/s11906-018-0875-x] [PMID: 29980865]
[135]
Koshimizu H, Kojima R, Okuno Y. Future possibilities for artificial intelligence in the practical management of hypertension. Hypertens Res 2020; 43(12): 1327-37.
[http://dx.doi.org/10.1038/s41440-020-0498-x] [PMID: 32655135]
[136]
Andrews LJB, Raja L, Shanmugasundaram S. Mobile android-based remote patient monitoring system through wearable sensors. J Discrete Math Sci Cryptogr 2019; 22(4): 557-68.
[http://dx.doi.org/10.1080/09720529.2019.1637156]
[137]
Adhikary R, Krishnakumar A, Kolwankar S, Shah A, Sanghavi S, Mattoo V. Effectiveness of digital therapeutics to improve blood pressure control among patients with hypertension and diabetes in India. J Am Coll Cardiol 2020; 75(11): 3583.
[http://dx.doi.org/10.1016/S0735-1097(20)34210-8]
[138]
Ganti VG, Carek AM, Nevius BN, Heller JA, Etemadi M, Inan OT. Wearable cuff-less blood pressure estimation at home via pulse transit time. IEEE J Biomed Health Inform 2021; 25(6): 1926-37.
[http://dx.doi.org/10.1109/JBHI.2020.3021532] [PMID: 32881697]
[139]
Alotaibi M, Uddin MA. Effectiveness of e-health systems in improving hypertension management and awareness: A systematic review. Trans Internet Inf Syst 2022; 16(1)
[http://dx.doi.org/10.3837/tiis.2022.01.010]
[140]
Majumder S. Wearable sensors for monitoring of physiological parameters and algorithms for extraction of clinically relevant information. IEEE Rev Biomed Eng 2017; 10: 86-99.
[http://dx.doi.org/10.1109/RBME.2017.2769423]
[141]
Elshawi R, Al-Mallah MH, Sakr S. On the interpretability of machine learning-based model for predicting hypertension. BMC Med Inform Decis Mak 2019; 19(1): 146.
[http://dx.doi.org/10.1186/s12911-019-0874-0] [PMID: 31357998]
[142]
Jha S, Topol EJ. Adapting to artificial intelligence: Radiologists and pathologists as information specialists. JAMA 2016; 316(22): 2353-4.
[http://dx.doi.org/10.1001/jama.2016.17438] [PMID: 27898975]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy